Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Dr Reddys Laboratories Ltd gained for a fifth straight session today. The stock is quoting at Rs 1287.7, up 0.02% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.07% on the day, quoting at 24697.95. The Sensex is at 80903.8, up 0.02%. Dr Reddys Laboratories Ltd has risen around 0.34% in last one month.
Meanwhile, Nifty Pharma index of which Dr Reddys Laboratories Ltd is a constituent, has risen around 4.31% in last one month and is currently quoting at 22761.15, up 1% on the day. The volume in the stock stood at 6.35 lakh shares today, compared to the daily average of 14.53 lakh shares in last one month.
The benchmark July futures contract for the stock is quoting at Rs 1292.8, up 0.46% on the day. Dr Reddys Laboratories Ltd is down 5.37% in last one year as compared to a 0.64% drop in NIFTY and a 6.72% drop in the Nifty Pharma index.
The PE of the stock is 15.58 based on TTM earnings ending June 25.
Bandhan Bank, RBL Bank and Indian Energy Exchange(IEX) shares are banned from F&O trading on 24 July 2025.
Upcoming Results:
Bajaj Finance, SBI Life Insurance, ACC, Mphasis, Nestle India, Adani Energy Solutions, V-Mart Retail, Aether Industries, Ajmera Realty & Infra India, Anant Raj, APL Apollo Tubes, Canara Bank, CG Power and Industrial Solutions, Coromandel International, KFin Technologies, LT Foods, Motilal Oswal Financial Services, Tatva Chintan Pharma, Ujjivan Small Finance Bank, UTI Asset Management Company will declare their result later today.
Stocks to Watch:
Tilaknagar Industries has signed definitive agreement to acquire the Imperial Blue business division from Pernod Ricard India via slump sale, for a lump sum consideration, basis enterprise value of euro 412.6 million (approximately Rs 4,150 crore as on date).
Dr Reddys Laboratories’ consolidated net profit increased 1.8% to Rs 1418.10 crore on 11.4% increase in net sales to Rs 8,545.20 crore in Q1 FY26 over Q1 FY25.
Infosys reported 1.59% decline in consolidated net profit to Rs 6,921 crore on 3.31% increase in revenue from operations to Rs 42,279 crore in Q1 FY26 over Q4 FY25. For FY26, the company has revised its revenue growth guidance to 1%–3% in constant currency (CC), up from the earlier range of 0%–3%. The operating margin forecast remains unchanged at 20%–22%.
CMS Info Systems’ consolidated net profit rose 3.1% to Rs 93.58 crore on 4.7% increase in net sales to Rs 627.41 crore in Q1 June 2025 over Q1 June 2024.
Force Motors reported a 52.4% jump in consolidated net profit to Rs 176.33 crore in Q1 FY26 compared with Rs 115.70 crore in Q1 FY25. Net sales increased 21.9% YoY to Rs 2297.25 crore in Q1 June 2025.
Bajaj Housing Finance’s standalone net profit jumped 20.9% to Rs 583.30 crore on 18.6% increase in total income to Rs 2,618.45 crore in Q1 FY26 over Q1 FY25.
Coforge reported 21.52% jump in consolidated net profit to Rs 317.40 crore in Q1 FY26 compared with Rs 261.20 crore in Q4 FY25. Net sales rose 8.17% QoQ to Rs 3,688.60 crore in Q1 FY26.
EBITDA for the quarter stood at Rs 2,278.4 crore, up 5.49% YoY.
In its global generics business, North America contributed Rs 3,412.3 crore in revenue, a 11% year-on-year decline. Revenue from Europe surged 142% to Rs 1,274.4 crore, The India business generated revenue of Rs 1,471.1 crore, registering an 11% YoY.
Revenue from Pharmaceutical Services and Active Ingredients (PSAI) came in at Rs 818.1 crore, a 7% YoY increase.
Co-Chairman & MD, G V Prasad, said: 'We delivered double-digit growth this quarter over the same period last year, reflecting our strength in branded markets and positive momentum in the Nicotine Replacement Therapy portfolio. The pricing pressure on Lenalidomide is expected to intensify in the U.S. generics market. We remain focused on strengthening our base business by delivery of our pipeline assets, improving overall productivity and business development.'
Hyderabad-based Dr. Reddy’s Laboratories is a global pharmaceutical company. It offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC.